


SCHEMA



- Accrual Goal: 176
1. Only patients who are HLA-A1+, HLA-A2+, or HLA-A3+ are eligible for this study.
 2. Patients will be administered each multi-epitope peptide vaccine intradermally (~50%) and subcutaneously (~50%) in two contiguous 1 ml aliquots. The vaccines will be administered on two extremities.
 3. Patients will be administered each multi-epitope peptide vaccine intradermally (~50%) and subcutaneously (~50%) in two contiguous 1 ml aliquots. The 3 vaccines and all subsequent repeat sets of vaccines (booster vaccines) will be administered on a single extremity. That extremity will be the extremity from which the sentinel immunized node was NOT removed.
 4. All patients will be followed for response until progression, and for survival for 5 years from study entry.
- NOTE: Submission of peripheral blood for use in ancillary studies described in Section 11.1 is mandatory. Collection time points and submission guidelines are described in Sections 7.2 and 11.1.